ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 12

Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

November 19, 2024

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center, Christine Bestvina, MD, University of Chicago, Hatim Husain, MD, Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center, Julia K. Rotow, MD

This episode explores management strategies for hematologic toxicities arising within the first 3 weeks of treatment with HER3-DXd, discusses the potential integration of HER3-DXd into clinical practice upon approval, and identifies unmet needs and suitable patient populations for future clinical trials evaluating HER3-DXd based on insights from the HERTHENA-Lung01 trial results.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP. 3: ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP. 4: Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP. 5: Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP. 6: Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP. 7: Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP. 8: Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

EP. 9: Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP. 10: Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP. 11: Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

Now Viewing

EP. 12: Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

EP. 13: HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC

EP. 14: Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02

EP. 15: Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

Video content above is prompted by the following:

Please discuss your management approach to hematologic toxicities, which might occur within the first 3 weeks of treatment with HER3-DXd.
If HER3-DXd is approved, where would you integrate HER3-DXd, and in what setting?
What are your thoughts on the unmet needs for HER3-DXd? Which patient populations may be the most appropriate for future clinical trials evaluating HER3-DXd, based on the HERTHENA-Lung01 results?